Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

Brexit to blame as firm plans to leave UK for Ireland

Tax-inversion deal brought company to UK - now Brexit causes a re-think

- PMLiVE

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

Lucid Magic

Lucid Group Communications Limited

- PMLiVE

Key considerations for disease- modifying Parkinson’s disease trials

‘Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development’

- PMLiVE

Moderna files record $500m IPO for RNA pipeline

Could be the largest IPO for a biotech start-up

- PMLiVE

MPs threaten to publish Vertex’s Orkambi price if no deal struck

Gives deadline of 30 November for long-running row to end

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

Novartis’ heart failure drug Entresto proves superior to enalapril

Results could see the drug strengthen its position in the market

Make your pharma exhibition stand paperless

Instead of providing delegates with something throwaway, consider going paperless. Say goodbye to printed leaflets and sheets and hello instant e-data downloads.

Apex Events and Exhibitions

- PMLiVE

Five things you didn’t realise you already know about influencer marketing

'When your objective is to build brand loyalty and trust, working with carefully-selected influencers could be the gateway to new audiences'

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

- PMLiVE

Google boosts healthcare business with new hire

Tech giant shows ambition in US market

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links